Products and Services for Diversifying Preclinical Models

AMSBIO has expanded its range of products and services dedicated to assisting scientists diversify their preclinical models effectively to help bridge the gender discrepancy gap in many areas of research.

Until 1993, most clinical trial participants were men of European descent, leading to a lack of data on the safety and efficacy of treatments for women and diverse populations. Although attitudes in clinical trials are changing, inclusivity in preclinical research is still often overlooked, leading to critical gaps in our understanding of how drugs and treatments affect different populations even before they proceed to human trials.

In a recent blog, to celebrate International Women’s Day, AMSBIO discusses the use of a proposed intestinal organoid biobank to combat accessibility issues as well as raising the issues of the lack of reporting by gender in COVID-19 vaccine development, where women had a disproportionate number of side-effects, under-reported due to aggregated data.

AMSBIO is a global provider of human and animal biospecimens to help increase diversity in research. The company’s extensive biorepository houses an array of tissues from reliable sources, including a comprehensive selection of healthy tissues as well as a variety of disease states from different genders and ethnicities. For specific research needs, AMSBIO additionally offers a custom tissue procurement service to supply the samples to match your research demands, however complex the donor demographics required.

In addition, leveraging a powerful combination of novel organoids with proprietary lab-on-a-chip technology from partners ScreenIn3D (S3D) – AMSBIO is uniquely placed to help preclinical researchers cost effectively develop high throughput data-rich assays.

Alex Sim, CEO of AMSBIO said “A significant driver for future clinical trials came from the US Federal Drug Administration in 2023. The new FDA 2.0 legislation adds a layer of stratification in research by creating more gender, race and other demographics requirements for clinical trials and research programs. Both AMSBIO and ScreenIn3D can help your research translate this for societal benefit and positioning of combination therapies”.

To read the informative new blog ‘Diversifying Preclinical Research’ please visit Or for further information about the AMSBIO biorepository please visit  or contact the company on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / [email protected].

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products, and services for R&D in the medical, nutrition, cosmetics, and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion, and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins, and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognized as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cells and cell therapy applications. This includes GMP cryopreservation technology, and high-quality solutions for viral delivery.

Automation Update